Evaluation for Potential Drug–Drug Interaction of MT921 Using In Vitro Studies and Physiologically–Based Pharmacokinetic Models

Evaluation for Potential Drug–Drug Interaction of MT921 Using In Vitro Studies and Physiologically–Based Pharmacokinetic Models

MT921 is a new injectable drug developed by Medytox Inc. to reduce submental fat. Cholic acid is the active pharmaceutical ingredient, a primary bile acid biosynthesized from cholesterol, endogenously produced by liver in humans and other mammals. Although individuals treated with MT921 could be adm...

Full description

Bibliographic Details
Main Authors: Hyo-jeong Ryu, Hyun-ki Moon, Junho Lee, Gi-hyeok Yang, Sung-yoon Yang, Hwi-yeol Yun, Jung-woo Chae, Won-ho Kang
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Pharmaceuticals
Subjects:
MT921
drug–drug interaction
in vitro studies
transporter
physiologically-based pharmacokinetic model
Online Access:https://www.mdpi.com/1424-8247/14/7/654

Similar Items

Similar Items